{"id":"NCT03169816","sponsor":"New York State Psychiatric Institute","briefTitle":"Lorcaserin in Combination With XR-Naltrexone for Relapse Prevention in Opioid Use Disorder","officialTitle":"Lorcaserin in Combination With XR-Naltrexone for Relapse Prevention in Opioid Use Disorder","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2017-05-25","primaryCompletion":"2019-08-30","completion":"2019-08-30","firstPosted":"2017-05-30","resultsPosted":"2020-10-05","lastUpdate":"2020-10-05"},"enrollment":60,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Opioid-use Disorder"],"interventions":[{"type":"DRUG","name":"Lorcaserin","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Lorcaserin","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study proposes to recruit patients with Opioid Use Disorder (OUD) seeking treatment into our program of outpatient detoxification and naltrexone induction followed by a relapse-prevention treatment with Extended release-naltrexone (XR-NTX) . Eligible participants will be randomly assigned to adjunctive treatment with lorcaserin (N = 40), or placebo (N = 20) with weekly therapy.","primaryOutcome":{"measure":"Proportion of Patients Successfully Inducted to Receive Naltrexone Injection","timeFrame":"Study week 1","effectByArm":[{"arm":"Lorcaserin","deltaMin":12,"sd":null},{"arm":"Placebo","deltaMin":7,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":1,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":33},"commonTop":["insomnia","GI Upset","Anorexia","Vomiting","Anxiety"]}}